Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | LATS1 | O95835 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21065336 | 0.84 | TDP1 (0.52) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL10049407 | 0.79 | TDP1 (0.47) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL571043 | 0.79 | TDP1 (0.52) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL22725572 | 0.78 | TDP1 (0.43) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL12287376 | 0.77 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL20687292 | 0.77 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL2562318 | 0.77 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL12775801 | 0.77 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL571410 | 0.77 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL861083 | 0.77 | TDP1 (0.46) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069322-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE FORMYLASE FOR TREATING MICROBIAL INFECTIONS | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2009-03-12 | — | — | US | disclosed |
| US-7173053-B2 | N-formyl hydroxylamine derivatives as inhibitors of bacterial polypeptide formylase for treating microbial infections | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| EP-1339400-B1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE DEFORMYLASE FOR TREATING MICROBIAL INFECTIONS | VERNALIS OXFORD LTD (GB) | 2005-06-29 | — | — | EP | disclosed |
| US-20040106666-A1 | Hydroxamic acid or n-formyl hydroxylamine derivatives as inhibitors of bakterial polypeptide deformylase for treating microbial infections | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
| CN-1127488-C | Compounds with growth hormone releasing properties | NOVO NORDISK AS (DK) | 2003-11-12 | — | — | CN | disclosed |
| EP-1339400-A1 | HYDROXAMIC ACID OR N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE DEFORMYLASE FOR TREATING MICROBIAL INFECTIONS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2003-09-03 | — | — | EP | disclosed |
| EP-0907643-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2003-01-15 | — | — | EP | disclosed |
| WO-2002041886-A1 | YDROXAMIC ACID OR N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BAKTERIAL POLYPEPTIDE DEFORMYLASE FOR TREATING MICROBIAL INFECTIONS | BRITISH BIOTECH PHARMACEUTICALS LTD (GB) | 2002-05-30 | — | — | WO | disclosed |
| US-5919777-A | PIPERAZINE DERIVATIVES USEFUL FOR TREATING MEDICAL DISORDERS RESULTING FROM A GROWTH HORMONE DEFIENCY | NOVO NORDISK A/S (DK) | 1999-07-06 | — | — | US | disclosed |
| CN-1216537-A | Compounds with growth hormone releasing properties | NOVO NORDISK AS (DK) | 1999-05-12 | — | — | CN | disclosed |
| EP-0907643-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997040023-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069322-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE FORMYLASE FOR TREATING MICROBIAL INFECTIONS | FPR1, FPR3, FPR2 | TDP1 2529/4885MAOA 176/4885MAOB 191/4885 |
| US-20040106666-A1 | Hydroxamic acid or n-formyl hydroxylamine derivatives as inhibitors of bakterial polypeptide deformylase for treating microbial infections | HNMT, ALKBH1, BAK1 | TDP1 590/4885MAOA 858/4885MAOB 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.